BlackRock Inc. Takes Position in Humana Inc. $HUM

Key Points

• BlackRock acquired 10.4 million Humana shares worth approximately $4.14 billion, giving it an 8.68% stake. Institutional investors collectively own 92.38% of the company.
• Analyst sentiment is mixed: 14 analysts rate Humana a Buy, 15 a Hold and one a Sell, producing a consensus Hold rating with a $395.22 price target.
• Humana reported quarterly EPS of $7.61, beating estimates of $7.27, while revenue rose 26.2% year over year to $40.89 billion. Shares recently opened at $382.13.

BlackRock Inc. purchased a new position in Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,417,803 shares of the insurance provider's stock, valued at approximately $4,138,160,000. BlackRock Inc. owned approximately 8.68% of Humana as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Trust Co. of Vermont acquired a new position in shares of Humana in the 2nd quarter worth approximately $28,000. Bogart Wealth LLC boosted its stake in Humana by 192.0% in the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after buying an additional 48 shares in the last quarter. Montag A & Associates Inc. boosted its stake in Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock valued at $25,000 after buying an additional 94 shares in the last quarter. Fideuram Asset Management Ireland dac bought a new stake in Humana in the fourth quarter valued at $27,000. Finally, Reflection Asset Management bought a new stake in Humana in the fourth quarter valued at $29,000. Institutional investors own 92.38% of the company's stock.

Wall Street Analyst Weigh In

HUM has been the subject of a number of analyst reports. Robert W. Baird set a $390.00 price objective on Humana in a report on Thursday, July 30th. HSBC lowered shares of Humana to a "hold" rating in a report on Thursday, July 30th. Oppenheimer reissued an "outperform" rating and set a $405.00 price target on shares of Humana in a report on Thursday, July 30th. Wolfe Research upgraded shares of Humana from a "peer perform" rating to an "outperform" rating in a research report on Thursday, July 30th. Finally, Zacks Research cut shares of Humana from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 11th. Fourteen analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $395.22.

Humana Price Performance

Shares of HUM stock opened at $382.13 on Wednesday. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $428.88. The stock has a market capitalization of $45.89 billion, a PE ratio of 36.15, a PEG ratio of 2.23 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. The stock's fifty day moving average is $382.93 and its 200-day moving average is $278.32.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. The business had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The firm's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same period in the previous year, the business posted $6.27 earnings per share. Equities research analysts expect that Humana Inc. will post 9.08 EPS for the current fiscal year.

Humana Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source